1st patient dosed in Phase 2b trial of SerpinPC for Hem B with inhibitors
The first participant has been dosed in a Phase 2b clinical trial that’s assessing the safety and efficacy of SerpinPC…
Articles by Marisa Wexler, MS
Platelets stripped of some sugar molecules may help with hemophilia
Treatment with platelets stripped of their natural sugar molecule coating helped to prevent inhibitors, or neutralizing antibodies, from forming against…
Altuviiio approved to treat hemophilia A in Japan and Taiwan
Altuviiio (efanesoctocog alfa) has been approved in Japan and Taiwan as a treatment to prevent and control bleeding in…
Idelvion controlled bleeds in small hemophilia B study
Treatment with Idelvion (albutrepenonacog alfa) was effective in a real-world setting at controlling bleeds for five people with…
FDA asked to update prescribing info on Altuviiio with new trial data
The U.S. Food and Drug Administration (FDA) is considering updating the prescribing information for Altuviiio (efanesoctocog alfa) to include…
P2C invests $250K in Anvesana to help advance mRNA therapies
To help advance new treatments for hemophilia and other blood disorders, Pathway to Cures (P2C) has invested $250,000…
First hemophilia A patient in Europe treated with commercial Roctavian
A person in Germany with severe hemophilia A has been treated with Roctavian (valoctocogene roxaparvovec-rvox), the first time…
Ixinity safely controls bleeds in young children with hemophilia B
Treatment with Ixinity (trenonacog alfa) can safely control bleeds in children younger than 12 with severe or moderately severe…
NHS advised not to cover hemophilia B treatment Hemgenix
The U.K.’s National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending that England’s National Health…
Roctavian, hemophilia A gene therapy, likely to soon arrive in US
Roctavian (valoctocogene roxaparvovec-rvox), the first gene therapy approved for adults with severe hemophilia A, is expected to be…